Drug Profile
TOUR 006
Alternative Names: PF-04236921; PF-4236921; TOUR-006Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Tourmaline Bio
- Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Graves ophthalmopathy
- Phase I Cardiovascular disorders
- Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 12 Apr 2024 Tourmaline Bio plans the phase II TRANQUILITY trial for Kidney disorders (SC), in April 2024 (NCT06362759)
- 19 Mar 2024 Tourmaline Bio plans a phase II trial for Cardiovascular disorders (SC) in first half of 2024
- 19 Mar 2024 Tourmaline Bio plans a phase III trial for Graves ophthalmopathy (SC) in 2024